{"Clinical Trial ID": "NCT00976989", "Intervention": ["INTERVENTION 1:", "T+P Anthracycline-based chemotherapy", "5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from cycle 7 to cycle 17 as adjuvant post-surgery therapy.", "INTERVENTION 2:", "T+P Sequential anthracycline chemotherapy", "- FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant treatment. Trastuzumab every three weeks from cycle 7 to cycle 21 as post-surgery adjuvant treatment."], "Eligibility": ["Incorporation criteria:", "Participating women, age >/=18", "Advanced, inflammatory or early unilateral invasive breast cancer", "HER2-positive breast cancer", "Initial left ventricular ejection fraction (LVEF) >/=55%", "- Exclusion criteria:", "\u2022 Metastatic disease (stage IV) or bilateral breast cancer", "Previous anticancer treatment or radiation therapy for malignancy", "Other malignancies, except in situ carcinoma of the cervix or basal cell carcinoma", "Clinically relevant cardiovascular disease", "Current chronic treatment with corticosteroids of >10mg methylprednisolone or equivalent"], "Results": ["Performance measures:", "Safety: Percentage of participants with symptomatic heart events assessed by the investigator", "- Left ventricular systolic dysfunction (LCVD) as evaluated by the investigator, including symptomatic Grade 3, 4 or 5 DVL with symptomatic heart events.", "Time limit: from base to about 3.5 years", "Results 1:", "Title of the arm/group: T+P Anthracycline-based chemotherapy", "Description of the arm/group: 5-Fluorouracil, epirubin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles followed by docetaxel, trastuzumab and pertuzumab every three weeks for three cycles as neoadjuvant therapy Trastuzumab every three weeks from cycle 7 to cycle 17 as post-surgery adjuvant therapy.", "Total number of participants analysed: 72", "Type of measurement: Number", "Unit of measure: % of participants 0", "Results 2:", "Title of the arm/group: Sequential anthracycline-based chemotherapy T+P", "Description of the arm/group: CSE every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant treatment. Trastuzumab every three weeks from cycle 7 to cycle 21 as post-surgery adjuvant treatment.", "Total number of participants analysed: 75", "Type of measurement: Number", "Unit of measure: percentage of participants 2.7"], "Adverse Events": ["Undesirable Events 1:", "Total: 23/72 (31.94 per cent)", "Febrile Neutropenia 10/72 (13.89 %)", "Neutropenia 2/72 (2.78 %)", "\u00b7 Leucopenia 2/72 (2.78 per cent)", "Thrombocytopenia 0/72 (0.00 %)", "- Left ventricular dysfunction 1/72 (1.39%)", "Cardiovascular disorders 0/72 (0.00 %)", "- Conduction disorder 0/72 (0.00 %)", "Diarrhoea 1/72 (1.39%)", "- Vomiting 0/72 (0.00 %)", "- Nausea 0/72 (0.00 %)", "Small intestinal obstruction 0/72 (0.00 %)", "Adverse Events 2:", "Total: 18/75 (24.0%)", "Febrile Neutropenia 4/75 (5.33%)", "Neutropenia 3/75 (4.0%)", "- Leucopenia 0/75 (0.00 %)", "Thrombocytopenia 0/75 (0.00 %)", "Left ventricular dysfunction 3/75 (4.0%)", "Cardiovascular disorders 0/75 (0.00 %)", "- Conduction disorder 0/75 (0.00 %)", "Diarrhoea 3/75 (4.0%)", "Vomiting 2/75 (2.67 %)", "Nausea 1/75 (1.33%)", "Small intestinal obstruction 0/75 (0.00 %)"]}